New Drug Evaluation

25th Feb 2020

The New Drug Evaluation for inhaled levodopa for the treatment of episodic motor fluctuations in Parkinson’s disease is now available to stakeholders. This publication provides a concise, structured evaluation of the efficacy, safety, and potential place in therapy for this newly licensed product.